Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-29

Clinical Trial Results: SPI-1005 Treatment in Severe COVID-19 Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SPI-1005 for treatment of severe COVID-19 has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPI-1005

Snippet

Sponsor: Sound Pharmaceuticals, Incorporated | Conditions: Covid19, Coronavirus | Phase 2 | Status: COMPLETED | Results posted: 2026-06-29